ID   K2 [Human melanoma]
AC   CVCL_AT85
DR   CLO; CLO_0037127
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_AT85
DR   Cell_Model_Passport; SIDM00126
DR   Cosmic; 888867
DR   Cosmic-CLP; 1298160
DR   DepMap; ACH-002147
DR   EGA; EGAS00001000978
DR   GDSC; 1298160
DR   LINCS_HMS; 51100
DR   LINCS_LDP; LCL-2091
DR   PharmacoDB; K2_722_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54899266
RX   PubMed=15009714;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Cosmic-CLP=1298160; DepMap=ACH-002147; PubMed=15009714).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.06%; Native American=0%; East Asian, North=0%; East Asian, South=1.34%; South Asian=0.87%; European, North=67.62%; European, South=30.11% (PubMed=30894373).
ST   Source(s): Cosmic-CLP=1298160
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 10,13
ST   D16S539: 10,13
ST   D5S818: 11
ST   D7S820: 10,11
ST   TH01: 7
ST   TPOX: 11
ST   vWA: 17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 02-05-16; Last updated: 02-05-24; Version: 18
//
RX   PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x;
RA   Tsao H., Goel V., Wu H., Yang G., Haluska F.G.;
RT   "Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1
RT   inactivation in melanoma.";
RL   J. Invest. Dermatol. 122:337-341(2004).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//